Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.

Catena KresbachLea HolstMelanie SchoofTara LevenCarolin GöbelSina NeyaziJacqueline TischendorfCarolin LooseAntonina WrzeszczTimur YorganStefan RutkowskiUlrich Schüller

Published in: Neuro-oncology (2023)

We conclude that intraventricular application of a SHH pathway inhibitor combines the advantages of a specific treatment agent with precise drug delivery and might evolve as a promising new way of targeted treatment for SHH MB patients.

Keyphrases

mouse model
drug delivery
end stage renal disease
chronic kidney disease
newly diagnosed
cancer therapy
prognostic factors
combination therapy